Merck & Co. Free cash flow decreased by 73.3% to $1.82B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 27.4%, from $2.51B to $1.82B. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 9.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong operational efficiency and the ability to self-fund future innovation or return capital to shareholders, while a decrease may indicate heavy capital expenditure cycles or declining operational profitability.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
High-growth semiconductor and AI infrastructure peers typically prioritize reinvestment, so free cash flow margins are often compared against R&D intensity and capital expenditure requirements of industry rivals.
cf_free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $505.00M | $3.63B | $3.89B | $3.78B | $3.17B | $4.48B | $3.28B | $332.00M | $2.74B | $6.82B | $0.00 | $2.23B | $4.85B | $8.51B | $2.51B | $1.17B | $2.53B | $6.84B | $1.82B |
| QoQ Change | — | +617.8% | +7.2% | -2.8% | -16.0% | +41.1% | -26.7% | -89.9% | +725.0% | +148.8% | -100.0% | — | +117.4% | +75.6% | -70.5% | -53.4% | +115.8% | +170.3% | -73.3% |
| YoY Change | — | — | — | — | +528.3% | +23.5% | -15.6% | -91.2% | -13.7% | +52.3% | -100.0% | +571.4% | +76.9% | +24.8% | — | -47.4% | -47.8% | -19.7% | -27.4% |